CD8A and neoplasm: Ex vivo-generated monocyte-derived DCs or blood DCs were loaded with tumor antigens in a variety of ways as therapeutic vaccines, and tumor-specific CD8+ T cell responses were detected in vaccinated patients with melanoma, prostate cancer, B cell lymphoma, acute myeloid leukemia, and myeloma.5